CAPR•benzinga•
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
Summary
FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 4, 2025 by benzinga